Clinical trial · Observational
Giessen Pulmonary Hypertension in Lung Cancer Registry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity in lung cancer patients. All information will be generated from the regular guidelines based course of treatment and there will be no interventions. This study will serve as a prospective register for all lung cancer patients treated at the university hospital Giessen.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pulmonary Hypertension Due to Lung Diseases and Hypoxia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| All lung cancer patients. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All lung cancer patients
- description
- There will not be an intervention.
- interventionNames
- Other: All lung cancer patients.
Primary outcomes (8)
- measure
- Pulmonary function test measured via Spirometry.
- timeFrame
- 2 years
- description
- vital capacity, total lung capacity, forced expiratory volume in one second, functional vital capacity, diffusing capacity for carbon monoxide, arterial partial pressure of oxygen; all measured as % of predicted normal values.
- measure
- sPAP values measured via Echocardiography.
- timeFrame
- 2 years
- description
- systolic pulmonary artery pressure (sPAP) measured in millimetre of mercury (mmHg).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with lung cancer at the University of Giessen lung Cancer Center. Exclusion Criteria: \-
References
Publications (2)
- BACKGROUNDPullamsetti SS, Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J, Weigert A, El-Nikhely N, Ghofrani HA, Krombach GA, Fink L, Gattenlohner S, Rapp UR, Schermuly RT, Grimminger F, Seeger W, Savai R. Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med. 2017 Nov 15;9(416):eaai9048. doi: 10.1126/scitranslmed.aai9048. PMID 29141888
- DERIVEDRako ZA, Cekay M, Yogeswaran A, Yildiz S, Arndt PF, Kremer N, Schafer S, Janetzko P, Thal BR, Mummert CM, Franken JK, Soethe H, Werner HF, Dumitrascu R, Grimminger F, Ghofrani HA, Pullamsetti SS, Seeger W, Naeije R, Savai R, Eul B, Tello K. Echocardiographic Measure of Right Ventricular-Pulmonary Arterial Coupling Predicts Survival in Lung Cancer. Ann Am Thorac Soc. 2025 Jul;22(7):1071-1078. doi: 10.1513/AnnalsATS.202409-949OC. PMID 40042816